Medical Devices Rules, 2017 Opens Up Enormous Opportunities
Bio Spectrum|November 2017

The new Medical Devices Rules, 2017 seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety. The rules will also regulate a much larger set of medical devices under a framework customized for medical devices. The stakeholders are hoping that the system will be industry friendly and will indeed create an ecosystem that will enable to boost medical technology innovation and manufacturing in the country.

Narayan Kulkarni
Medical Devices Rules, 2017 Opens Up Enormous Opportunities

On January 31, 2017 the Ministry of Health and Family Welfare has notified Medical Devices Rules, 2017. The new Rules have been framed in conformity with Global Harmonisation Task Force (GHTF) framework and conform to best international practices. The rules will come in to force with effect from January 1, 2018. Only 15 categories of medical devices are, at present, regulated as drugs and to that extent, the current regulatory practices in India were not fully geared to meet the requirements of medical devices sector in the country.

Medical devices will, under the new Rules, be classified as per GHTF practice, based on associated risks, into Class A (low risk), Class B (low moderate risk), Class C (moderate high risk) and Class D (high risk). The manufacturers of medical devices will be required to meet risk proportionate regulatory requirements that have been specified in the Rules and are based on best international practices.

With a view to bring in the highest degree of professionalism in regulation of medical devices, a system of ‘Third Party Conformity Assessment and Certification’ through Notified Bodies is envisaged. The Notified Bodies will be accredited by the National Accreditation Board for Certification Bodies (NABCB). The NABCB will, before accrediting Notified Bodies, assess their competence in terms of required human resources and other requirements. These Bodies will undertake verification and assessment of Quality Management System of Medical Device Manufacturers of Class A and Class B category and may, on as required basis, be called upon to render assistance for regulation of Class C and D medical devices also.

Diese Geschichte stammt aus der November 2017-Ausgabe von Bio Spectrum.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

Diese Geschichte stammt aus der November 2017-Ausgabe von Bio Spectrum.

Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.

WEITERE ARTIKEL AUS BIO SPECTRUMAlle anzeigen
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Bio Spectrum

Sartorius Stedim Biotech opens new centre for bioprocess innovation in US

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.

time-read
1 min  |
BioSpectrum India Jan 2025
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Bio Spectrum

Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research

Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.

time-read
1 min  |
BioSpectrum India Jan 2025
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Bio Spectrum

Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data

Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.

time-read
1 min  |
BioSpectrum India Jan 2025
Parse Biosciences announces expansion of Evercode BCR product line
Bio Spectrum

Parse Biosciences announces expansion of Evercode BCR product line

Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.

time-read
1 min  |
BioSpectrum India Jan 2025
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
Bio Spectrum

New technology for unambiguous detection of HIV genome using tailored fluorogenic tests

A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.

time-read
1 min  |
BioSpectrum India Jan 2025
Gene mutation likely cause for developing autism in early childhood: RGCB study
Bio Spectrum

Gene mutation likely cause for developing autism in early childhood: RGCB study

Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.

time-read
1 min  |
BioSpectrum India Jan 2025
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
Bio Spectrum

IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing

A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.

time-read
1 min  |
BioSpectrum India Jan 2025
RSSDI study lays focus on Yoga and Diabetes Prevention
Bio Spectrum

RSSDI study lays focus on Yoga and Diabetes Prevention

Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.

time-read
1 min  |
BioSpectrum India Jan 2025
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
Bio Spectrum

Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare

RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).

time-read
1 min  |
BioSpectrum India Jan 2025
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Bio Spectrum

Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser

Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.

time-read
1 min  |
BioSpectrum India Jan 2025